Journalartikel

Autorenliste: Panagiotidis, GD; Müller, C; Binder, M; Weber, F

Jahr der Veröffentlichung: 2023

Zeitschrift: Archives of Virology

Bandnummer: 168

Heftnummer: 2

ISSN: 0304-8608

eISSN: 1432-8798

Open Access Status: Hybrid

DOI Link: https://doi.org/10.1007/s00705-022-05696-0

Verlag: Springer

Abstract: 

Influenza A virus (FLUAV) is a significant human pathogen. In silico structural analysis (PMID 28628827) has suggested that the FDA-approved drug paliperidone interferes with the binding of the FLUAV polymerase subunit PB2 to the nucleoprotein NP. We found that paliperidone inhibits FLUAV A/PR/8/34 early after infection of canine MDCK II, human A549, and human primary bronchial cells, but not at late time points. No effect was detectable against the strains A/Hamburg/05/2009 and A/WSN/33. Moreover, paliperidone indeed disturbed the interaction between the PB2 and the NP of A/PR/8/34 and reduced early viral RNA and protein synthesis by approximately 50%. Thus, paliperidone has measurable but transient and virus-strain-restricted effects on FLUAV.

Harvard-Zitierstil: Panagiotidis, G., Müller, C., Binder, M. and Weber, F. (2023) Influenza A virus strain PR/8/34, but neither HAM/2009 nor WSN/33, is transiently inhibited by the PB2-targeting drug paliperidone, Archives of Virology, 168(2), Article 63. https://doi.org/10.1007/s00705-022-05696-0

APA-Zitierstil: Panagiotidis, G., Müller, C., Binder, M., & Weber, F. (2023). Influenza A virus strain PR/8/34, but neither HAM/2009 nor WSN/33, is transiently inhibited by the PB2-targeting drug paliperidone. Archives of Virology. 168(2), Article 63. https://doi.org/10.1007/s00705-022-05696-0